Radionuclide-Drug Conjugates (RDCs)
Radionuclide-drug conjugates (RDCs) are one of the most promising development directions for nuclear drug targeted therapy. RDC is composed of targeting element, linker, chelate and radioactive isotope. RDC has advantages in early tumor diagnosis, treatment and postoperative tumor evaluation. The same ligand can be connected to nuclides used for disease diagnosis and treatment respectively, promoting the integration of diagnosis and treatment of RDC drugs. This entry provides molecular intermediates that can be used in the synthesis and research of RDC.
Radionuclide-Drug Conjugates (RDCs) Isoform Specific Products
All Product Categories
-
Radionuclide-Drug Conjugates (RDCs) Related Products (226)
Related Products (226)
-
Radionuclide-Drug Conjugates (RDCs) Isoform Comparison
-
NOTA-COG1410
0 ImagesCat. No.: HY-P10220CAS No.: 2914099-35-5NOTA-COG1410 forms triggering receptor expressed on myeloid cells 2 (TREM2) targeting ligand. NOTA-COG1410 is capable of being labelled with 68Gallium (68Ga) for discovery and diagnosis of digestive system tumors through positron emission tomography/computed tomography (PET/CT). NOTA-COG1410 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
-
NH2-PEG4-NODA-GA
0 ImagesCat. No.: HY-164588CAS No.: 2306108-46-1NH2-PEG4-NODA-GA is a NODA-type metal chelator that can bind to radionuclides to prepare radionuclide drug conjugates (RDCs). RDCs have the ability to specifically target biomolecules and can be used in medical imaging or therapy.
-
DOTA-Lanreotide
0 ImagesCat. No.: HY-P10730CAS No.: 213187-44-1DOTA-Lanreotide is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy.
-
FAP targeting peptide-PEG2 conjugate
0 ImagesCat. No.: HY-P10946CAS No.: 3076328-71-4FAP targeting peptide-PEG2 conjugate (Example A1) is the peptide (HY-P10945) and linker conjugate of Unlabeled FXX489 (HY-P10944). Unlabeled FXX489 is a fibroblast activation protein (FAP)-targeting ligand.
-
NOTA-SP2A-PSMAL
0 ImagesCat. No.: HY-181853NOTA-SP₂A-PSMAL is a ligand targeting prostate-specific membrane antigen (PSMA), which competitively binds to PSMA with high binding affinity and an IC50 value of 0.26 nM. 18F-labeled NOTA-SP2A-PSMAL can be used as a PET tracer for positron emission tomography imaging of prostate cancer. NOTA-SP2A-PSMAL can be used for the synthesis and research of radionuclide conjugates (RDCs).
-
NOTA trihydrochloride
0 ImagesCat. No.: HY-134418ACAS No.: 133256-65-2NOTA (trihydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. NOTA (trihydrochloride) can be used for conjugation of peptides and radionuclides.
-
Galacto-RGD
0 ImagesCat. No.: HY-P5053CAS No.: 922175-70-0Galacto-RGD is an RGD analogue that can be coupled with the radioactive isotope 18F and used as an integrin α β selective tracer. Galacto-RGD can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
-
(S)-NH2-NODAGA hydrochloride
0 ImagesCat. No.: HY-164575CPurity: 99.91%(S)-NH2-NODAGA hydrochloride is the S isomer of NH2-NODAGA hydrochloride (HY-164575B). NH2-NODAGA hydrochloride is an amino-modified NODAGA-type bifunctional chelator, specifically designed for amidation coupling with targeting ligands via squaric acid (SA), followed by coordination with radionuclides (e.g., 68Ga, 177Lu). NH2-NODAGA hydrochloride can be coupled with diethyl squarate to form a PSMA inhibitor conjugate, which is used in prostate cancer research.
-
VCAM1 binding peptide
0 ImagesCat. No.: HY-P11088CAS No.: 1311293-04-5VCAM1 binding peptide is a VCAM1 binder with internalization activity. VCAM1 binding peptide can be labeled with 5-FAM. VCAM1 binding peptide serves as a component of biosensing systems for visualizing in vitro VCAM1 endocytic pathways. VCAM1 binding peptide forms the research and development basis for MacroP and NAMP, PET radiotracers targeting VCAM1. VCAM1 binding peptide is applicable to studies related to atherosclerosis.
-
DOTA-NAPamide
0 ImagesCat. No.: HY-P10731CAS No.: 935886-72-9DOTA-NAPamide is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy.
-
(R)-NODAGA-tris(t-Bu ester)
0 ImagesCat. No.: HY-W591317CAS No.: 1252799-47-5Synonyms: (R)-NODAG(R)-NODAGA-tris(t-Bu ester) ((R)-NODAG) is a NODAGA derivative. (R)-NODAGA-tris(t-Bu ester) can be used to label peptides, antibodies, etc., and subsequently radiolabeled for PET imaging.
-
Fluoroestradiol
0 ImagesCat. No.: HY-180306CAS No.: 84693-92-5Fluoroestradiol is an Estrogen receptor PET imaging tracer precursor. Fluoroestradiol, when radiolabeled with 18F, can be used as an Estrogen receptor PET imaging tracer. 18F-Fluoroestradiol exhibits the highest uptake selectivity and target-to-background ratio among
several 18F-labeled estrogens. 18F-Fluoroestradiol has demonstrated Estrogen receptor expression in normal brain tissues and in meningiomas. 18F-Fluoroestradiol can quantify regional Estrogen receptor expression in breast cancer. 18F-Fluoroestradiol has potential applications in assessing and monitoring heterogeneity in ovarian cancer.
-
NOTA-Octreotide
0 ImagesCat. No.: HY-P0036DCAS No.: 1427427-01-7NOTA‑Octreotide is a selective SSTR2‑targeting PET tracer. NOTA‑Octreotide binds specifically to SSTR2 and accumulates in SSTR2‑expressing tissues. NOTA‑Octreotide enables effective imaging of somatostatin receptor‑positive tumors in mice and shows high specific uptake in SSTR2‑expressing organs in healthy rats. NOTA-Octreotide can be used for PET imaging investigation of neuroendocrine tumors..
-
JR11-PEG3-DOTA-PSMA-03
0 ImagesCat. No.: HY-P11488JR11-PEG3-DOTA-PSMA-03 (Compound 2) is an RDC-related compound containing the chelating agent DOTA (HY-W053583), the JR11 peptide (SSTR2 antagonist), and the PSMA ligand. JR11-PEG3-DOTA-PSMA-03 shows SSTR2-binding affinities and PSMA-binding affinities, with IC50 s of 94.0 nM, 81.8 nM, respectively. JR11-PEG3-DOTA-PSMA-03 can be radiolabeled with [68Ga]. [68Ga] radiolabeled JR11-PEG3-DOTA-PSMA-03 can be used in diagnostic studies of neuroendocrine differentiated prostate cancer.
-
THP(Bz)3-NH2 TFA
0 ImagesCat. No.: HY-164591ATHP(Bz)3-NH2 TFA is a bifunctional chelator that can be conjugated with radionuclides to prepare radionuclide conjugates (RDCs).
-
Ac-crown-TATE
0 ImagesCat. No.: HY-P11900Ac-crown-TATE is an actinium-labeled radioligand derived from the SSTR2 agonist crown-TATE, which targets neuroendocrine tumors with high SSTR2 expression. The [226Ac]Ac-crown-TATE form of Ac-crown-TATE possesses both SPECT-detectable γ-emission and α-radiation properties, and it inhibits tumor growth and prolongs survival. Ac-crown-TATE can be used in studies of SSTR2-positive neuroendocrine tumors, targeted α-radiation, and radionuclide imaging.
-
NP1
0 ImagesCat. No.: HY-P11859NP1 is a NOTA-chelated linear precursor based on the ROR1-targeting peptide. After labeling with [18F]AlF, NP1 yields [18F]AlF-NP1, a PET imaging probe with excellent ROR1 specificity (KD = 141.7 nM), rapid tumor uptake and high target-to-background ratio, which is suitable for non-invasive visualization of various ROR1-overexpressing tumors.
-
MMA-NODAGA TFA
0 ImagesCat. No.: HY-160607APurity: 98.02%MMA-NODAGA TFA is a chelator for site-specific labeling of targeting proteins containing unpaired cysteine. MMA-NODAGA TFA can be used to conjugate with exosome and 64Cu in image with positron emission tomography (PET).
-
DOTA-bis(tert-butyl)ester
0 ImagesDOTA-bis(tert-butyl)ester is a DOTA-based metal chelator that can bind to radionuclides and is used to prepare radionuclide conjugates (RDCs). DOTA-bis(tert-butyl)ester can be conjugated with different salts to form different metal chelators, such as (HY-B1244) hydrochloride to obtain DOTA-MN2. DOTA-MN2 can be reacted with [67]Ga-citrate to obtain radiolabeling. When (67)Ga-DOTA-MN2 is incubated in phosphate buffer solution or mouse plasma for 24 hours, it does not undergo significant decomposition. In the biodistribution experiment of NFSa tumor mice, it has high tumor uptake and rapid plasma clearance, and is a good material for SPECT and PET studies.
